Patents by Inventor Lin Tung GUEY
Lin Tung GUEY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240024506Abstract: This disclosure relates to mRNA therapy for the treatment of propionic acidemia (PA). mRNAs for use in the invention, when administered in vivo, encode human propionyl-CoA carboxylase alpha (PCCA) and/or human propionyl-CoA carboxylase beta (PCCB), and isoforms thereof, functional fragments thereof, and fusion proteins comprising PCCA and/or PCCB. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of propionyl-CoA carboxylase (PCC) expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of disease-associated toxic metabolites associated with deficient PCCA or PCCB activity, in subjects.Type: ApplicationFiled: June 1, 2023Publication date: January 25, 2024Inventors: Lei Jiang, Lin Tung Guey, Paolo G. V. Martini, Vladimir Presnyak
-
Publication number: 20230323371Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.Type: ApplicationFiled: April 6, 2023Publication date: October 12, 2023Inventors: Paolo MARTINI, Stephen G. HOGE, Kerry BENENATO, Vladimir PRESNYAK, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Xuling ZHU, Lin Tung GUEY, Staci SABNIS
-
Patent number: 11649461Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.Type: GrantFiled: September 13, 2019Date of Patent: May 16, 2023Assignee: ModernaTX, Inc.Inventors: Paolo Martini, Stephen G. Hoge, Kerry Benenato, Vladimir Presnyak, Iain Mcfadyen, Ellalahewage Sathyajith Kumarasinghe, Xuling Zhu, Lin Tung Guey, Staci Sabnis
-
POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA
Publication number: 20230112986Abstract: The invention relates to mRNA therapy for the treatment of Acute Intermittent Porphyria (AIP). mRNAs for use in the invention, when administered in vivo, encode human porphobilinogen deaminase (PBGD), isoforms thereof, functional fragments thereof, and fusion proteins comprising PBGD. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to affect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PBGD expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient PBGD activity in subjects, namely porphobilinogen and aminolevulinate (PBG and ALA).Type: ApplicationFiled: July 21, 2022Publication date: April 13, 2023Applicants: ModernaTX, Inc., Fundacion Para La Investigacion Medica AplicadaInventors: Paolo MARTINI, Stephen HOGE, Kerry BENENATO, Vladimir PRESNVAK, Lei JIANG, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Antonio FONTANELLAS ROMA, Pedro BERRAONDO LOPEZ, Matias Antonio AVILA ZARAGOZA, Lin Tung GUEY, Staci SABNIS -
Publication number: 20220370354Abstract: This disclosure relates to mRNA therapy for the treatment of methylmalonic acidemia (MMA). mRNAs for use in the invention, when administered in vivo, encode methylmalonyl-CoA mutase (MUT). mRNA therapies of the disclosure increase and/or restore deficient levels of MUT expression and/or activity in subjects.Type: ApplicationFiled: May 8, 2020Publication date: November 24, 2022Inventors: Tal Zaks, Kelly Lindert, Lin Tung Guey
-
Publication number: 20220265856Abstract: This disclosure relates to mRNA therapy for the treatment of propionic acidemia (PA). mRNAs for use in the invention, when administered in vivo, encode human propionyl-CoA carboxylase alpha (PCCA) and/or human propionyl-CoA carboxylase beta (PCCB), and isoforms thereof, functional fragments thereof, and fusion proteins comprising PCCA and/or PCCB. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of propionyl-CoA carboxylase (PCC) expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of disease-associated toxic metabolites associated with deficient PCCA or PCCB activity, in subjects.Type: ApplicationFiled: November 21, 2018Publication date: August 25, 2022Applicant: ModernaTX, Inc.Inventors: Lei Jiang, Lin Tung Guey, Paolo G.V. Martini, Vladimir Presnyak
-
Publication number: 20220071915Abstract: The invention relates to mRNA therapy for the treatment of Citrullinemia Type 2 (“CTLN2”). mRNAs for use in the invention, when administered in vivo, encode human Citrin, isoforms thereof, functional fragments thereof, and fusion proteins comprising Citrin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of Citrin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of biomarkers associated with deficient Citrin activity in subjects, namely ammonia and/or triglycerides.Type: ApplicationFiled: January 21, 2021Publication date: March 10, 2022Applicant: ModernaTX, Inc.Inventors: Paolo Martini, Stephen Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Jingsong Cao, Lin Tung Guey, Staci Sabnis
-
Patent number: 10993918Abstract: The invention relates to mRNA therapy for the treatment of Citrullinemia Type 2 (“CTLN2”). mRNAs for use in the invention, when administered in vivo, encode human Citrin, isoforms thereof, functional fragments thereof, and fusion proteins comprising Citrin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of Citrin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of biomarkers associated with deficient Citrin activity in subjects, namely ammonia and/or triglycerides.Type: GrantFiled: May 18, 2017Date of Patent: May 4, 2021Assignee: ModernaTX, Inc.Inventors: Paolo Martini, Stephen Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Jingsong Cao, Lin Tung Guey, Staci Sabnis
-
Publication number: 20200149052Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.Type: ApplicationFiled: September 13, 2019Publication date: May 14, 2020Inventors: Paolo MARTINI, Stephen G. HOGE, Kerry BENENATO, Vladimir PRESNYAK, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Xuling ZHU, Lin Tung GUEY, Staci SABNIS
-
POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA
Publication number: 20200085916Abstract: The invention relates to mRNA therapy for the treatment of Acute Intermittent Porphyria (AIP). mRNAs for use in the invention, when administered in vivo, encode human porphobilinogen deaminase (PBGD), isoforms thereof, functional fragments thereof, and fusion proteins comprising PBGD. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to affect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PBGD expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient PBGD activity in subjects, namely porphobilinogen and aminolevulinate (PBG and ALA).Type: ApplicationFiled: May 18, 2017Publication date: March 19, 2020Inventors: Paolo Martini, Stephen Hoge, Kerry Benenato, Vladimir Presnyak, Lei Jiang, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Antonio Fontanellas Roma, Pedro Berraondo Lopez, Matias Antonio Avila Zaragoza, Lin Tung Guey, Staci Sabnis -
Patent number: 10519455Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.Type: GrantFiled: August 23, 2018Date of Patent: December 31, 2019Assignee: ModernaTX, Inc.Inventors: Paolo Martini, Stephen G. Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Xuling Zhu, Lin Tung Guey, Staci Sabnis
-
Patent number: 10494636Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.Type: GrantFiled: August 23, 2018Date of Patent: December 3, 2019Assignee: ModernaTX, Inc.Inventors: Paolo Martini, Stephen G. Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Xuling Zhu, Lin Tung Guey, Staci Sabnis
-
Publication number: 20190175517Abstract: The invention relates to mRNA therapy for the treatment of Citrullinemia Type 2 (“CTLN2”). mRNAs for use in the invention, when administered in vivo, encode human Citrin, isoforms thereof, functional fragments thereof, and fusion proteins comprising Citrin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of Citrin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of biomarkers associated with deficient Citrin activity in subjects, namely ammonia and/or triglycerides.Type: ApplicationFiled: May 18, 2017Publication date: June 13, 2019Inventors: Paolo Martini, Stephen Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Jingsong Cao, Lin Tung Guey, Staci Sabnis
-
Publication number: 20190000933Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.Type: ApplicationFiled: August 23, 2018Publication date: January 3, 2019Inventors: Paolo MARTINI, Stephen G. HOGE, Kerry BENENATO, Vladimir PRESNYAK, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Xuling ZHU, Lin Tung GUEY, Staci SABNIS
-
Publication number: 20190002890Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.Type: ApplicationFiled: August 23, 2018Publication date: January 3, 2019Inventors: Paolo MARTINI, Stephen G. HOGE, Kerry BENENATO, Vladimir PRESNYAK, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Xuling ZHU, Lin Tung GUEY, Staci SABNIS
-
Publication number: 20190000932Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the ?-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.Type: ApplicationFiled: August 23, 2018Publication date: January 3, 2019Inventors: Paolo MARTINI, Stephen G. HOGE, Kerry BENENATO, Vladimir PRESNYAK, Iain MCFADYEN, Ellalahewage Sathyajith KUMARASINGHE, Xuling ZHU, Lin Tung GUEY, Staci SABNIS